-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Early breast cancer patients who are positive for estrogen and/or progesterone are able to benefit from hormone therapy, however, the global high burden of death due to high prevalence and long-term risk of recurrence requires biomarkers to guide other treatments.
In a forward-looking, observational study, panel, which uses 360 genes for breast cancer, tested the expression of 612 tumor genes in patients treated with tymoxifen or aromatase inhibitors in early post menophageal breast cancer to analyze 23 breast cancer pathfages.
candidate markers associated with disease subtypes and event-free survival (EFS) were obtained through clustering analysis, Cox models, and conditional inference trees, and 613 breast marker patients were independently tested.
the tumor-soaked lymphocytes (TIL) on tissue slices and the mutation burden of 36 tumors was assessed by sequencing the whole exon group.
the PAM50-derived classification method distinguishes low-risk (Luminal A) from high-risk sub-type (Luminal B).
in high-risk patients, shorter EFSs were associated with low androgen subjects (HR 3.61) or high BRCAness characteristic expression (HR 3.58).
BRCAness has been independently proven to be a predictor of EFS shortening (HR 2.64).
about 13-15% of patients, rich in high-level, high-risk subsypes, with tumor inflammation characteristics (TIS) of high expression, suggesting that the anti-tumor immune response is inhibited.
TIS score was associated with a strong number of TIL, but not with tumor mutation status.
, BRCA-related DNA repair defects and tumor immunoreactive inhibition may be clinically relevant predictors of endocrine therapy, complementing treatment options for hormone-sensitive early breast cancer substations.
.